Back to News
Market Impact: 0.25
Unicycive Jumps As FDA Accepts Kidney Drug Resubmission; March 2027 Decision Set
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted Unicycive Therapeutics’ resubmitted New Drug Application for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease. Acceptance is a regulatory-process milestone, not FDA approval; the article excerpt provides no review timeline or other figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
UNCY0.55
More News
- FDA accepts Unicycive resubmission for kidney drug application
- New Mexico took on Meta alone and won a $25 billion judgment over Facebook’s privacy violations
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Judge orders Meta to pay $25bn in fines for Facebook privacy violations
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Meta ordered to pay $25 billion in penalties over the Cambridge Analytica scandal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can ChatGPT or Claude Replace a Research Platform?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance